AtheroGenics AGI-1067 Pivotal Data Expected In Late Q1
This article was originally published in Pharmaceutical Approvals Monthly
AtheroGenics’ atherosclerosis drug candidate AGI-1067 may qualify for multiple labeling claims in patient subpopulations including elderly patients, diabetics and women, CEO Russell Medford stated during the JP Morgan Healthcare Conference in San Francisco Jan. 10.
You may also be interested in...
Pfizer ups ante on Exubera approval with full license: Pfizer's decision to acquire Sanofi-Aventis' marketing rights to Exubera suggests the company is confident that the inhaled insulin product will receive FDA approval. Exubera's user fee date is Jan. 27, following a three-month extension resulting from an FDA request for additional technical chemistry data. Pfizer announced Jan. 12 that it will acquire worldwide rights for the development, production and commercialization of Exubera for $1.3 bil. - building on the firms' previous co-development alliance. The deal follows a judge's ruling that Sanofi's purchase of Aventis constituted a change-in-control under Pfizer and Aventis' 1998 agreement for Exubera. The NDA was submitted in March (1Pharmaceutical Approvals Monthly March 2005, p. 12)...
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011